Repositioning PARP inhibitors in the treatment of thoracic malignancies
The evaluation of the homologous recombination repair (HRR) status is emerging as a predictive tumor agnostic biomarker for poly (ADP-ribose) polymerase (PARP) inhibition across different tumor types and testing for HRR-signature is currently a developing area with promising therapeutic implications. Treatment with PARP inhibitors (PARPi) either as single agent or in combination with chemotherapy have shown so far limited activity in patients with thoracic malignancies. A deeper understanding of the biological background underlying HRR-deficient tumors, along with the recent advent of new effective targeted and immunotherapeutic agents, prompted the design of a new generation of clinical trials investigating novel PARPi-combinations in patients with lung cancer as well as malignant pleural mesothelioma .
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, Elena Parlagreco, Francesca Jacobs, Angela List ì, Luisella Righi, Paolo Bironzo, Silvia Novello, Giorgio Vittorio Scagliotti Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Gastroschisis Repair | Lung Cancer | Mesothelioma